August 1, 2016Circulation Arrhythmia and Electrophysiology
Long-Term Outcomes of Catheter Ablation of Ventricular Tachycardia in Patients With Cardiac Sarcoidosis
Key result
Catheter ablation in patients with cardiac sarcoidosis and ventricular tachycardia achieved an overall VT-free survival of 55% at 2-year follow-up.
Why the study?
Does catheter ablation improve VT-free survival and reduce VT burden in patients with cardiac sarcoidosis and ventricular tachycardia?
Population
31 patients with a diagnosis of cardiac sarcoidosis based on Heart Rhythm Society criteria and ventricular…
Design
Cohort
Follow-up
median 2.5 (range, 0-10.5) years
Authors
Discussion
Loading...
Member takes
Implication
May support ablation for VT control in cardiac sarcoidosis; hypothesis-generating and requires prospective trials before practice change.
Key Points
- This research aims to evaluate the long-term outcomes of catheter ablation for ventricular tachycardia in patients with cardiac sarcoidosis.
- Enrolled 31 patients with cardiac sarcoidosis and ventricular tachycardia for catheter ablation.
- Conducted preprocedure cardiac MRI and PET imaging for 74% of participants.
- Followed up for a median duration of 2.5 years to assess outcomes.
- Overall VT-free survival was 55% at 2-year follow-up.
- Abnormal PET findings were present in 15 of 23 cases, with significant VT burden reduction observed post-ablation.
- Factors like late gadolinium enhancement and positive baseline PET predicted higher recurrence risk.
Study Design
Type
Cohort (n=31)
Structured PICO
Does catheter ablation improve VT-free survival and reduce VT burden in patients with cardiac sarcoidosis and ventricular tachycardia?
P
Population
31 patients (mean age 55±10 years) with a diagnosis of cardiac sarcoidosis based on Heart Rhythm Society criteria and ventricular tachycardia (VT).
I
Intervention
Catheter ablation (CA) of ventricular tachycardia
O
Outcome
Overall VT-free survival and reduction of VT burdenhard clinical
Catheter ablation is effective in achieving long-term freedom from VT or reducing VT burden in patients with cardiac sarcoidosis, though positive baseline PET and LGE predict worse arrhythmia-free survival.
Cite This Study
Muser et al. (2016) conducted a cohort in Cardiac sarcoidosis and ventricular tachycardia (n=31). Catheter ablation was evaluated on Overall VT-free survival at 2-year follow-up. Catheter ablation in patients with cardiac sarcoidosis and ventricular tachycardia achieved an overall VT-free survival of 55% at 2-year follow-up.